Newamsterdam Pharma Company N.v. · NASDAQ:NAMS

Newamsterdam Pharma — Q1 2026 Earnings Presentation

6 slides from Newamsterdam Pharma's earnings presentation, May 7, 2026

  1. Slide 1: PREVAIL Update

    > _\ ~~ 8 = PREVAIL Update May 7, 2026 tk NewAmsterdam Pharma

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and the accompanying oral statements made by NewAmsterdam Pharma Company N.V. (“NewAmsterdam”, the “Company” or “we”) in connection herewith (collectively, this “Presentation”) contains forward-looking statements within the meaning of the U.S. Private Sec

  3. Slide 3: Explaining BROADWAY's Observed 21% MACE-4 Reduction

    Explaining BROADWAY’s Observed 21% MACE-4 Reduction Obicetrapib’s Observed MACE-4 Reduction Methods of Estimating MACE-4 Reduction 1% Additional Reduction Based on the CTT line, the expectation for a 33% reduction in LDL-C from placebo would be a 9% 5% Lp(a) MACE-4 reduction, after 12 months LDL-P r

  4. Slide 4: Kaplan-Meier Curve Separates at Day 200

    Kaplan-Meier Curve Separates at Day 200 Driven by Attenuation of MACE- 4 Events in the Obicetrapib Arm Kaplan Meier Curve Landmark Analysis: Censored at 6 months 4-point MACE: CHD death, Non-fatal myocardial infarction, non-fatal stroke, coronary revascularization 4 While not powered to detect a MAC

  5. Slide 5: BROADWAY Designed to be a Predictor of PREVAIL

    BROADWAY Designed to be a Predictor of PREVAIL 1º endpoint – week 12 N = 2532 LDL-C endpoint N = 9541 Obicetrapib 10 mg (2:1 randomization) 13-months Obicetrapib 10 mg (1:1 randomization) Placebo Placebo 13-months 54-months Key Inclusion Criteria Key Inclusion Criteria • ASCVD or HeFH • LDL-C≥ 100 m

  6. Slide 6: Analysis of BROADWAY and PREVAIL Year 1 Event Rates

    Analysis of BROADWAY and PREVAIL Year 1 Event Rates(1) Blinded/Blended Year 1 Event Rates 4-point MACE: CHD death, Non-fatal myocardial infarction, non-fatal stroke, coronary revascularization (1) While not powered to detect a MACE benefit, we observed positive MACE-4 data as part of our review of t

NewAmsterdam Pharma Company — Q1 2026 Earnings Presentation on 6ix